674 related articles for article (PubMed ID: 25300870)
1. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
2. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
[TBL] [Abstract][Full Text] [Related]
4. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Jabbour E; Cortes J; Santos FP; Jones D; O'Brien S; Rondon G; Popat U; Giralt S; Kebriaei P; Jones RB; Kantarjian H; Champlin R; de Lima M
Blood; 2011 Mar; 117(13):3641-7. PubMed ID: 21156844
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
10. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
11. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
12. [Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Wang J; Zhang Y; Zu Y; Li Z; Li M; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):110-4. PubMed ID: 27014979
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
Xu LP; Huang XJ; Liu KY; Chen H; Liu DH; Zhang YC; Chen YH; Han W; Gao ZY; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):231-5. PubMed ID: 15968308
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
Chen H; Liu KY; Xu LP; Chen YH; Zhang XH; Wang Y; Qin YZ; Liu YR; Lai YY; Huang XJ
Leuk Res; 2017 Aug; 59():136-141. PubMed ID: 28654842
[TBL] [Abstract][Full Text] [Related]
17. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
Jones D; Kamel-Reid S; Bahler D; Dong H; Elenitoba-Johnson K; Press R; Quigley N; Rothberg P; Sabath D; Viswanatha D; Weck K; Zehnder J
J Mol Diagn; 2009 Jan; 11(1):4-11. PubMed ID: 19095773
[TBL] [Abstract][Full Text] [Related]
18. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
Arpinati M; Tolomelli G; Bochicchio MT; Castagnetti F; Amabile M; Bandini G; Bonifazi F; Stanzani M; Rosti G; Martinelli G; Baccarani M
Biol Blood Marrow Transplant; 2013 May; 19(5):735-40. PubMed ID: 23333776
[TBL] [Abstract][Full Text] [Related]
19. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
